(Q39697622)

14 September 2017

title

An evaluation of risk factors for adverse drug events associated with angiotensin-converting enzyme inhibitors (English)

1 reference

14 September 2017

8

David W Bates

1 reference

14 September 2017

Takeshi Morimoto

1

1 reference

14 September 2017

Tejal K Gandhi

2

1 reference

14 September 2017

Julie M Fiskio

3

1 reference

14 September 2017

Andrew C Seger

4

1 reference

14 September 2017

Joseph W So

5

1 reference

14 September 2017

E Francis Cook

6

1 reference

14 September 2017

Tsuguya Fukui

7

1 reference

14 September 2017

publication date

1 November 2004

1 reference

Journal of Evaluation in Clinical Practice

14 September 2017

published in

1 reference

14 September 2017

volume

10

1 reference

14 September 2017

issue

4

1 reference

14 September 2017

page(s)

499-509

1 reference

Detecting adverse events using information technology

14 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2753.2003.00484.X

Error in medicine: what have we learned?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2753.2003.00484.X

Effect of computerized physician order entry and a team intervention on prevention of serious medication errors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2753.2003.00484.X

Has the survival of the heart failure population changed? Lessons from trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2753.2003.00484.X

Drug complications in outpatients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2753.2003.00484.X

Adverse Drug Events in Ambulatory Care

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2753.2003.00484.X

Angiotensin II receptor blockers: equal or preferred substitutes for ACE inhibitors?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2753.2003.00484.X

Fatal hyperkalemia related to combined therapy with a COX-2 inhibitor, ACE inhibitor and potassium rich diet

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2753.2003.00484.X

Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy. A review of the literature and pathophysiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2753.2003.00484.X

A remarkable medical story: benefits of angiotensin-converting enzyme inhibitors in cardiac patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2753.2003.00484.X

Adverse effects of enalapril in the Studies of Left Ventricular Dysfunction (SOLVD). SOLVD Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2753.2003.00484.X

What practices will most improve safety? Evidence-based medicine meets patient safety

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2753.2003.00484.X

Bradykinin-mediated angioedema

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2753.2003.00484.X

Perindopril postmarketing surveillance: a 12 month study in 47,351 hypertensive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2753.2003.00484.X

Angiotensin converting enzyme inhibition in heart failure: clinical trials and clinical practice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2753.2003.00484.X

Formulating clinical strategies for angiotensin antagonism: a review of preclinical and clinical studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2753.2003.00484.X

Intermediate but not low doses of aspirin can suppress angiotensin-converting enzyme inhibitor-induced cough

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2753.2003.00484.X

10.1111/J.1365-2753.2003.00484.X

21 January 2018

Identifiers

DOI

1 reference

14 September 2017

1 reference